Lexatumumab
Drug Information | |||
---|---|---|---|
Image | |||
Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL |
Chemical Data
C H N O Molecular Weight |
Lexatumumab is a human monoclonal antibody designed for the treatment of tumors. It targets the TRAIL receptor 2 (also known as DR5 or death receptor 5), which is a member of the tumor necrosis factor (TNF) receptor superfamily. Lexatumumab is classified as a TRAIL receptor agonist.
Mechanism of Action[edit | edit source]
Lexatumumab binds to the TRAIL receptor 2 on the surface of cancer cells, which activates the receptor's apoptotic pathway. This leads to the induction of programmed cell death, or apoptosis, in the tumor cells. The activation of this pathway is selective for cancer cells, sparing most normal cells, which makes TRAIL receptor agonists a promising therapeutic approach in oncology.
Clinical Trials[edit | edit source]
Lexatumumab has been evaluated in several clinical trials for its effectiveness and safety in treating various types of cancers, including non-small cell lung cancer, colorectal cancer, and Hodgkin's lymphoma. The trials have focused on assessing the drug's efficacy both as a monotherapy and in combination with other chemotherapeutic agents.
Development and Regulatory Status[edit | edit source]
As of the last update, lexatumumab is still in the investigational stages and has not received approval from regulatory bodies such as the Food and Drug Administration (FDA) for general medical use. It is currently under development by Human Genome Sciences, Inc.
Potential and Challenges[edit | edit source]
While lexatumumab has shown potential in preclinical and early clinical studies, the development of TRAIL receptor agonists faces several challenges. These include the variability in response among patients and the potential development of resistance to the therapy. Further research is needed to fully understand the mechanisms of action, optimize dosing regimens, and identify patient populations that might benefit the most from this treatment.
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD